The present disclosure describes a method for treatment of pre-eclampsia including treatment with Extended Release L-triiodothyronine (T3) and thyroxine (T4). In an alternate composition and method Extended Release T3, T4, and at least one phosphodiesterase (PDE) inhibitor, being a combined 3/4 or a PDE inhibitor, or a combination of these PDE inhibitors may be used for treatment.

The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.

Pharmaceutical coatings obtained from coating compositions based on film-forming copolymers of N,N-diethylaminoethyl methacrylate (DEAEMA) and methyl methacrylate (MMA) comprising a weight ratio of DEAEMA:MMA in the range of 35:65 to 55:45, where the copolymers are present partially neutralized with C.sub.3-C.sub.10-dicarboxylic acids.

Disclosed is a selenium-doped black phosphorus prodrug comprising selenium-doped black phosphorus nanosheets and polyethylene glycol amine coating the surface of the selenium-doped black phosphorus nanosheets. The selenium-doped black phosphorus nanosheets comprise black phosphorus nanosheets and selenium elements doped in the black phosphorus nanosheets, with the selenium elements replacing positions of a portion of the phosphorus atoms in the black phosphorus crystal lattice. The selenium-doped black phosphorus prodrug is a controlled-release prodrug of selenium elements, which can realize the near-infrared light controlled-release of selenium elements, thereby controllably regulating selenium content in the human body, regulating human immunity, and preventing and treating cancers. Also provided is a method for preparing the selenium-doped black phosphorus prodrug.

The present invention provides a new use for cannabinoids in the prevention of pre-cachexia or cachexia in a patient suffering from cancer, wherein said cannabinoid is administered at low dosage and wherein administration is started prior to chemotherapy and is maintained for at least the duration of the chemotherapy.

Injectable depot compositions comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.

Disclosed is a pharmaceutical formulation containing esomeprazole or a pharmaceutically acceptable salt thereof. The pharmaceutical formulation, based on considerably improved pH-dependent drug release characteristics, starts to release the esomeprazole or a pharmaceutically acceptable salt thereof at a target delay time after oral administration, continues the release for a predetermined time, and finishes the release after a predetermined time, thereby providing excellent patient convenience and excellent therapeutic effects, as compared to conventional other formulations.

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Improved methods of treating prostate cancer by vascular-targeted photodynamic therapy, and improved methods of planning treatment, are presented using a light density index to plan and guide effective treatment.